Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage

Running title: Müller cell-derived VEGF in diabetic retinopathy

Juanjuan Wang1,2,5, Xueliang Xu1, Michael H. Elliott3,6, Meili Zhu2,5, Yun-Zheng Le2,4,5,6

1Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, 410008, China, Departments of 2Medicine Endocrinology, 3Ophthalmology, 4Cell Biology, and 5Harold Hamm Oklahoma Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA; 6Dean A. McGee Eye Institute, Oklahoma City, OK, 73104, USA

Correspondence to:
Yun-Zheng Le
E-mail: Yun-Le@ouhsc.edu


This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
**Objective:** Vascular endothelial growth factor (VEGF-A or VEGF) is a major pathogenic factor and therapeutic target for diabetic retinopathy (DR). Since VEGF has been proposed as a survival factor for retinal neurons, defining the cellular origin of pathogenic VEGF is necessary to the effectiveness and safety of long-term anti-VEGF therapies for DR. To determine the significance of Müller cell-derived VEGF in DR, we disrupted VEGF in Müller cells with an inducible Cre/lox system and examined diabetes-induced retinal inflammation and vascular leakage in these conditional VEGF knockout (KO) mice.

**Research Design and Methods:** Leukostasis was determined by counting the number of fluorescently labeled leukocytes inside retinal vasculature. Expression of biomarkers for retinal inflammation was assessed by immunoblotting of TNF-α, ICAM-1, and NF-κB. Vascular leakage was measured by immunoblotting of retinal albumin and fluorescent microscopic analysis of extravascular albumin. Diabetes-induced vascular alterations were examined by immunoblotting and immunohistochemistry for tight-junctions and by trypsin digestion assays for acellular capillaries. Retinal integrity was analyzed with morphological and morphometric analyses.

**Results:** Diabetic conditional VEGF KO mice exhibited significantly reduced leukostasis, expression of inflammatory biomarkers, depletion of tight-junction proteins, numbers of acellular capillaries, and vascular leakage compared to diabetic control mice.

**Conclusions:** Müller cell-derived VEGF plays an essential and causative role in retinal inflammation, vascular lesions, and vascular leakage in DR. Therefore, Müller cells are a primary cellular target for pro-inflammatory signals that mediates retinal inflammation and vascular leakage in DR.

**Diabetic retinopathy (DR)** is a micro-vascular complication of diabetes and a leading cause of vision loss in working aged adults in developed countries. During diabetes, hyperglycemia and oxidative stress up-regulates a major angiogenic factor, vascular endothelial growth factor (VEGF-A or VEGF), which induces retinal neovascularization, vascular leakage, and perhaps macular edema (1, 2). DR is also known as a chronic inflammatory disorder. During the early stage of DR, pro-inflammatory proteins, such as intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor-α (TNF-α), are up-regulated, and increased leukostasis is observed (3-5). These early pathological changes are associated with up-regulation of VEGF (6-8).

Clinical observations that elevated VEGF levels are associated with DR have led to intensive studies on VEGF action over the past decade and have resulted in anti-VEGF treatments as a major therapeutic strategy for DR. Surprisingly the role of VEGF in the pathogenesis of DR has not been well-investigated at the cellular level. Since VEGF may be required for the maintenance and
Müller cell-derived VEGF in diabetic retinopathy

survival of retinal neurons (9-12), revealing cellular mechanism of VEGF actions becomes necessary to the safety and effectiveness of anti-VEGF therapies.

In the retina VEGF is mainly expressed in Müller cells (13), endothelial cells (14), astrocytes (15), retinal pigment epithelium (RPE) (16), and ganglion cells (17). At present, the in vivo function of VEGF produced by these retinal cell-types remains largely uninvestigated. While the role of retinal Müller cell-produced VEGF in DR was probed a decade ago (13), its function in the disease is unclear. An in vitro study demonstrated that Müller cells produce a large amount of VEGF in response to hypoxia (14). This led to speculation that Müller cells are a major source of VEGF in DR and a major cellular target for the treatment of the disease. To determine the role of Müller cell-derived VEGF and dissect the cellular mechanism of DR, we generated conditional VEGF knockout (KO) mice by mating floxed VEGF mice with transgenic mice expressing Cre recombinase in retinal Müller cells (18, 19), with a Cre/lox based conditional gene KO approach (for review, see (20)). Using these conditional VEGF KO mice, we recently demonstrated that Müller cell-derived VEGF contributed significantly to ischemia-induced retinal neovascularization (21). This report describes our investigation on the role of Müller cell-derived VEGF in retinal inflammation and vascular leakage that occurs as a consequence of diabetes.

MATERIALS AND METHODS

Treatment of Conditional VEGF Knockout Mice: All animal experiments followed the guidelines established by the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committees. Conditional VEGF KO mice were generated by mating floxed VEGF mice with transgenic mice expressing Cre recombinase in retinal Müller cells, as described previously (18, 19, 21). Doxycycline was administered through the drinking water of pregnant mothers at a concentration of 2 mg/mL in 5% sucrose from embryonic day 15 to postnatal day 1. To minimize the influence of genetic background, littermates were used as controls in this study. PCR analysis of tail DNA was performed for genotyping mice using primer pairs a (5'-CCT GGC CCT CAA GTA CAC CTT -3’) and b (5’-TCC GTA CGA CGC ATT TCT AG-3’) to detect a 108-bp product for the WT allele and a 148-bp product for the floxed VEGF allele (21). Primer pairs c (5’-AGG TGT AGA GAA GGC ACT TAG C-3’) and d (5’-CTA ATC GCC ATC TTC CAG CAG G-3’) were used to detect a 411-bp product for Cre (22).

Diabetes was induced in 6 to 10 week-old mice (weighing 18-22 g). After an 8-hour fast, mice were injected intraperitoneally with freshly prepared streptozotocin (STZ; Sigma, St. Louis, MO) at a concentration of 55 mg/kg body weight in 10 mM citrate buffer (pH 4.5), daily for 5 days. Age-matched controls received citrate buffer only. Mice with blood glucose levels greater than 300 mg/dL seven days after the first STZ-injection were deemed diabetic.

Immunoblotting and Immunohistochemistry:

For immunoblotting, retinas were dissected and sonicated in a lysis buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5%
deoxycholate, and a protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN), which is similar to that used for successful extraction of occludin previously (23). The lysate was centrifuged at 14,000 rpm for 10 minutes at 4°C and the supernatant was collected. Monoclonal antibody against β-actin (1:5000 dilution) was from Sigma (St. Louis, MO); polyclonal antibodies against VEGF, ICAM-1, occludin, hypoxia-inducible factor-1α (HIF-1α), nuclear factor-kappaB (NF-κB, p65), and phosphorylated NF-κB (p65) (1:500 dilution) were from Santa Cruz Biotechnology (Santa Cruz, CA), polyclonal antibody against TNF-α (1:500 dilution) was from Abcam (Cambridge, MA); polyclonal antibody against Zonula occludens 1 (ZO-1, 1:500 dilution) was from Zymed (San Francisco, CA); and polyclonal antibody against albumin (1:1000 dilution) was from Bethyl (Montgomery, TX). Horseradish peroxidase-linked anti-rabbit, mouse, or goat IgG (1:2000 dilution, Santa Cruz Biotechnology) were used for secondary detection in immunoblotting. Immunoreactivity was visualized by enhanced chemiluminescence using Super Signal West Dura Extended Duration Substrate (Pierce Biotechnology, Inc., Rockford, IL) and images were captured by a Chemi Genius Image Station (SynGene, Frederick, MD). Band intensities were quantified using the GENETOOLS program (SynGene). Immunohistochemical staining was performed according to a previous method (21).

Quantification of Retinal Leukostasis:
Quantification of leukostasis was performed as described previously (24, 25). The chest cavity of deeply anesthetized mice was carefully opened. The descending aorta was clamped and a perfusion needle was inserted into the left ventricle. The perfusate was drained by cutting the right atrium immediately prior to perfusion. Mice were perfused with 10 mL of phosphate-buffered saline (PBS) and heparin (0.1 mg/mL) to wash out non-adherent blood cells. FITC-conjugated concanavalin A (ConA) (20 μg/mL in PBS; pH 7.4; 5 mg/kg body weight; Vector Laboratories, Burlingame, CA) was then perfused to label adherent leukocytes and vascular endothelial cells. Unbound ConA was flushed by perfusion with 10 mL PBS. Eyes were removed and were fixed in 4% paraformaldehyde for 1 h. Retinas were dissected and flat-mounted. Images of retinas were observed by epifluorescence or confocal microscopy and the total number of adherent leukocytes per retina was counted.

Visualization and Quantification of Retinal Vascular Leakage: Anesthetized mice received femoral vein injection of fluorescein isothiocyanate-bovine serum albumin (FITC-BSA, 100 mg/kg) (Sigma). After 20 min mice were euthanized and eyes were removed and fixed in 4% paraformaldehyde for 30 min. Retinas were dissected, flat mounted, and imaged by fluorescent microscopy. A computer-assisted method was used to quantify leakage using Adobe Photoshop 7.0 software. In this procedure, the intensity of basal level of fluorescence in non-leakage areas was used as background fluorescence. After deduction of background signals, the total intensity of fluorescence contributed by the leaked FITC-labeled albumin was used to represent the leakage.

Quantification of Retinal Vascular Histopathology: Retinal vasculature was isolated by the trypsin digest method (26). Briefly, 10% buffered formalin-fixed retinas
were dissected, washed, and incubated with 3% Difco crude trypsin (BD Biosciences, Sparks, MD) containing 0.2 M NaF at 37°C for 1 hour. Retinal tissues were brushed away, and the isolated vasculature was mounted, dried on glass slides, and stained with periodic acid-Schiff and hematoxylin. Acellular capillaries were counted in six field areas in the mid-retina (400 × magnification) and expressed as the total number/mm of retina area.

**Retinal Morphometry and Transmission Electron Microscopy:** Transmission electron microscopy (TEM) was performed as described previously (27). Morphometric analysis of hematoxylin and eosin (H&E)-stained retinal sections was performed as described previously (21). The total number of ganglion nuclei in H&E-stained retinal sections was used to represent ganglion cell density.

**Statistic Analysis:** All results required statistic analysis were expressed as the mean ± SEM. Statistical significance was evaluated by t-test with \( p \) value < 0.05 considered to be significant.

**RESULTS**

**Preparation of Diabetic Conditional VEGF Knockout Mice:** In an effort to generate human *VMD2* promoter controlled tetracycline-inducible RPE-specific Cre mice (28), we identified a mouse line displaying Cre function predominantly localized to the retinal Müller cells (29). Further characterization demonstrated that this mouse line is feasible for conditional gene expression in Müller glia (19). The transgenic Cre mice (cre+) were mated with mice carrying a floxed VEGF (Vegf\(^{f/f}\)) allele (18) to generate the conditional Müller glial VEGF KO mice. Using primary cultures derived from the conditional VEGF KO mice, we determined that there was a 66.5% reduction of VEGF expression in Müller cells (21). Immunoblotting assays demonstrated a significant decrease (43.2%) in VEGF expression in the retinas of conditional VEGF KO mice (cre\(^{+}\)Vegf\(^{f/f}\)) compared with WT (cre\(^{-}\)Vegf\(^{f/f}\)) controls (Figure 1A), confirming that Müller cells are a major source of VEGF in the retina.

Diabetes was induced by STZ-injection in conditional VEGF KO mice and WT controls. Blood glucose levels and average body weights of mice at the time of experiments are shown in Table 1. A significant elevation of blood glucose level and loss of body weight were observed in diabetic groups compared with non-diabetic controls (\( p < 0.001 \)), two and six months after induction of diabetes. No significant changes in blood glucose levels or body weight were observed between conditional VEGF KO and WT mice under normal or diabetic conditions (Table 1), indicating that disruption of Müller cell-derived VEGF did not affect blood glucose levels or body weight. Under diabetic stress, expression of VEGF increased dramatically (2.16-fold) in WT mice (Figure 1A). In contrast, disruption of Müller cell-derived VEGF resulted in a 51.4% reduction in VEGF (Figure 1A). This result was supported by immunohistochemical analysis in conditional VEGF KO mice subjected to a diabetic stress (Figure 1C-D). As HIF-1α is up-regulated in diabetic retinas and contributes to increased levels of VEGF (30), we verified the state of hypoxia in conditional VEGF KO mice by measuring the expression of HIF-1α in diabetic retinas. Our results demonstrated a greater than 2-fold up-
regulation of HIF-1α (Figure 1B) in diabetic retinas of both WT and conditional VEGF KO mice, which is consistent with a previous observation (31). However, no significant difference was observed in HIF-1α levels between WT and conditional VEGF KO mice, suggesting that the loss of Müller cell-derived VEGF did not alter diabetes-induced HIF-1α accumulation.

**Retinal Inflammatory Responses:**
Leukostasis, a major parameter for inflammation and early pathological changes in DR, was quantified by FITC-conjugated ConA staining assay two months after inducing diabetes (3). Under normal conditions, the number of adherent leukocytes in the retinal microvasculature of WT and conditional VEGF KO mice was negligible (data not shown). The number of adherent leukocytes in the retinal microvasculature of diabetic WT mice was elevated significantly and was increased 3-fold compared with that in diabetic conditional VEGF KO mice (Figure 2C).

To verify if disrupting Müller cell-derived VEGF significantly reduced retinal inflammation, we examined the expression of pro-inflammatory markers ICAM-1 and TNF-α by immunoblotting. Retinas from diabetic WT mice demonstrated a greater than 2-fold increase in the levels of both ICAM-1 and TNF-α, compared with those from non-diabetic animals (Figure 2D-E). No apparent increases in ICAM-1 and TNF-α were observed in diabetic conditional VEGF KO mice. These results suggest that the loss of Müller cell-derived VEGF significantly reduces inflammation in diabetic retinas.

The transcription factor NF-κB is activated in diabetes and plays a major role in diabetes-induced early pathological changes in DR (32, 33). To determine the relationship between Müller cell-derived VEGF and NF-κB in diabetic retinas, we investigated the level and phosphorylation state at serine 276 of NF-κB p65 subunit, as phosphorylation of this subunit increases transcripational activity of NF-κB (34). While there was no detectable difference in the overall level of NF-κB p65 subunit between diabetic conditional VEGF KO and control mice, loss of Müller cell-derived VEGF resulted in a 2-fold decrease in phosphorylated NF-κB p65 in the retinas two months after diabetes (Figure 2F), suggesting that Müller cell-derived VEGF regulates NF-κB transcriptional activity in DR.

**Retinal Vascular Histopathology and Leakage:**
To determine the role of Müller cell-derived VEGF in vascular leakage, we performed immunoblotting for extravascular albumin content in the retinas and vitreous from PBS-perfused mice six months after inducing diabetes. The extravascular albumin content in diabetic WT mice was 2.5-fold higher than that in non-diabetic WT mice (Figure 3A). However, there was a 58.9% reduction of extravascular albumin in the retinas and vitreous of diabetic conditional VEGF KO mice (Figure 3A). Using FITC-labeled albumin, we visualized and quantified vascular leakage in conditional VEGF KO mice six months after inducing diabetes (Figure 3B-F). Compared to diabetic WT mice, diabetic conditional VEGF KO mice had significantly fewer areas of leaked FITC-labeled albumin (arrows in Figure 3C, E) in their retina. Computer-assisted quantitative analysis demonstrated a similar level of reduction (61.5%) of FITC-labeled albumin leakage in diabetic conditional VEGF KO mice compared to diabetic WT controls (Figure 3F).
To determine the mechanism of Müller cell-derived VEGF in diabetes-induced vascular leakage, we examined the expression of occludin and ZO-1, two important tight junction proteins. While diabetes caused 39.2% and 58.1% decreases of retinal occludin and ZO-1 in WT mice, virtually no change in retinal occludin and ZO-1 contents were observed in diabetic conditional VEGF KO mice (Figure 4A-B). Compared with WT controls, the diabetic conditional VEGF KO mice demonstrated 59.7% and 130.3% increases of occludin and ZO-1 in their retinas (Figure 4A-B). This result was confirmed by immunohistochemical analysis of ZO-1 in retinal vessels (Figure 4C-F). Our results suggest that the loss of Müller cell-derived VEGF significantly reduced diabetes-induced retinal vascular leakage by attenuating the depletion of occludin and ZO-1.

To assess retinal vascular lesions, we quantified the number of acellular capillaries in trypsin digestion assay and examined basement membrane thickness by TEM in conditional VEGF KO mice six months after inducing diabetes. The diabetic conditional VEGF KO mice had significantly fewer acellular capillaries than diabetic WT controls (Figure 5A-C). However, we did not observe significant differences in basement membrane thickness between diabetic conditional VEGF KO and WT mice and between diabetic and non-diabetic mice (Figure 5D-F).

**Morphometric and Ultrastructural Analyses:** To determine if the loss of Müller cell-derived VEGF in the conditional VEGF KO mice affected retinal neuron survival, we examined retinal integrity in conditional VEGF KO mice six months after inducing diabetes. Retinal morphology was carefully examined and retinal thickness, a direct correlation of retinal neuronal number, was quantified by morphometry. No significant differences in outer nuclear layer, inner nuclear layer, or whole retina were observed between diabetic conditional VEGF KO mice and WT controls (Figure 6A-C), indicating no loss in photoreceptors or inner retinal neurons. In addition, we counted the number of ganglion cells and observed no differences between diabetic conditional VEGF KO mice and WT controls (Figure 6F). Furthermore, no morphological changes indicative of neuronal apoptosis were observed at the ultrastructural level (Figure 6D-E). These results suggest that disrupting VEGF from Müller glia does not result in enhanced neuronal loss in conditional VEGF KO mice six months after inducing diabetes.

**DISCUSSION**

VEGF is produced by multiple cellular origins in the retina and has paracrine activity. To date, no in vivo study has convincingly demonstrated the cellular origin of VEGF induced in DR. Since VEGF has been suggested to play a role in retinal neuron survival and choriocapillaris fenestration (9-12) and anti-VEGF treatments have become a major therapeutic strategy for DR, revealing the cellular origin(s) of pathogenic VEGF becomes paramount. Müller cells have long been suspected as a major contributor to DR (13). Due to the lack of appropriate animal models (35), in vivo function of Müller cell-derived VEGF in DR remained unaddressed until recently when we developed an inducible Cre/lox system to delete VEGF from Müller cells (19).

Increased VEGF levels in DR are responsible for blood-retina barrier (BRB)
breakdown and lead to vascular leakage (36). However, the causative role of Müller cell-derived VEGF in diabetes-induced BRB breakdown has not been established. In this study, we demonstrate that the loss of Müller cell-derived VEGF significantly inhibits diabetes-induced vascular leakage (Figure 3). Since the integrity of tight junction proteins in endothelial cells is crucial for BRB function, we measured retinal tight-junction proteins occludin and ZO-1 (Figure 4) to determine how increases in Müller cell-derived VEGF might result in diabetes-induced vascular leakage. Our result that diabetes-induced depletion of occludin and ZO-1 was attenuated in conditional VEGF KO mice supports a role for Müller cell-derived VEGF in diabetes-induced reorganization of tight junctions (37-39). Our results also suggest that reducing Müller cell-derived VEGF attenuates capillary acellularity (Figure 5A-C), a relatively early vascular lesion in diabetic rodent retinas. Since VEGF is a survival factor for endothelial cells, one might expect that reducing VEGF levels might accelerate endothelial loss and the development of acellular capillaries in diabetic retinas, which is contrary to our observation. However, our result is consistent with that in a study demonstrating an increase in acellular capillaries in transgenic mice over-expressing VEGF165 from rod photoreceptors (40). As inflammation may play a central role in developing pathological changes, including acellular capillaries in DR (41), we speculate that the diabetes-induced inflammatory responses may play a more prominent role in endothelial death and capillary acellularity and that the reduced inflammatory responses in diabetic conditional VEGF KO mice may attenuate the development of acellular capillaries. Furthermore, as we did not disrupt VEGF in endothelial cells, autocrine endothelium-derived VEGF signaling could play a role in promoting endothelial survival and in reducing capillary acellularity in diabetic conditional VEGF KO mice. Based on our results, we cannot conclude if the Müller cell-derived VEGF plays a role in the thickening of basement membranes, as we did not observe significant change in this process between diabetic mice and non-diabetic controls six month after STZ-injection (Figure 5A-C). This result is in agreement with a previous observation in similar aged diabetic and non-diabetic mice (42).

Leukostasis, adhesion of leukocytes to the vascular wall, is increased in the diabetic retina and results in retinal vascular occlusion (5). The diabetes-induced leukostasis is mediated via up-regulation of ICAM-1 and its ligand CD18 (3). Disruption of ICAM-1 and CD18 in mice result in decreases in both leukostasis and vascular permeability (41). It has been shown that VEGF increases expression of ICAM-1 in endothelial capillaries and intravitreal injection of VEGF up-regulates the level of retinal ICAM-1 (8). TNF-α is an inflammatory cytokine which is up-regulated in diabetic retinas. It has also been reported that an inhibitor of TNF-α is capable of reducing diabetes-induced leukostasis and BRB breakdown (41) and that anti-VEGF treatment inhibited the expression of TNF-α (43). In the current report, we demonstrate that disrupting Müller cell-derived VEGF inhibits diabetes-induced leukostasis and overexpression of ICAM-1 and TNF-α (Figure 2), early pathological changes in DR. We also demonstrated that disruption of Müller cell-derived VEGF
caused a significant reduction of phosphorylated NF-κB p65 subunit (Figure 2F), suggesting that reduced transcriptional activation affects downstream effectors for inflammatory responses and vascular complications in diabetic retinas (44, 45).

Diabetic conditional VEGF KO mice and non-diabetic WT mice produced a comparable level of VEGF (Figure 1A). This level of VEGF may not exceed the threshold of causing significant pathological changes in DR, as observed throughout this study. Very low levels of retinal inflammation and vascular leakage and the inability for other retinal VEGF-producing cells to compensate the loss of VEGF in diabetic conditional VEGF KO mice only suggest that Müller cell-derived VEGF is a primary source of VEGF involved in the diabetes-induced retinal inflammation and vascular leakage. However, we cannot exclude the possibility that VEGF derived from other retinal cells contributes to diabetes-induced retinal inflammation and vascular leakage. In this study, HIF-1α expression was up-regulated in the retinas of diabetic conditional VEGF KO mice and WT controls, which is consistent with a previous finding that HIF-1α is increased in diabetic retina and that inducing HIF-1α contributes to the increased levels of VEGF (30). However, loss of Müller cell-derived VEGF did not alter the expression of HIF-1α in diabetic retina (Figure 1B). This result indicates that the phenotypic changes observed in the conditional VEGF KO mice are not attributed to the altered expression of the up-stream regulator HIF-1α. Therefore, the reduction of diabetes-induced retinal inflammation and vascular leakage in the conditional VEGF KO mice appears to be a direct consequence of reduced VEGF expression. This result may suggest that HIF-1α is a potential target for a more stringent therapeutic strategy to treat DR, which is supported by a recent finding that inhibition of HIF-1α has an effect on ischemia-induced vascular leakage (46).

We demonstrated that disrupting Müller cell-derived VEGF did not cause significant changes in retinal morphology/morphometry in diabetic conditional VEGF KO mice six months after STZ-injection (Figure 6), suggesting that the reduction in VEGF level may not be sufficient to cause accelerated retinal neuron loss within the time frame. Therefore, the phenotypic changes described herein can be directly attributed to the disruption of Müller cell-derived VEGF, not the loss of retinal neurons. Since Cre expression in retinal ganglion cells is negligible (19), the reduced retinal inflammation and vascular leakage in our conditional VEGF KO mice is unlikely caused by disruption of VEGF in ganglion cells. The inability for ganglion cells to compensate for the loss of Müller cell-produced VEGF in conditional VEGF KO mice may suggest that the major function of ganglion cell-derived VEGF is not pathogenic, and is perhaps important for neuronal survival under stress conditions (10, 11). A significant decrease of VEGF produced by retinal endothelial cells under hyperglycemia suggests a minor role for endothelial cell-derived VEGF in the pathogenesis of DR (47). The role of the RPE-derived VEGF in DR is intriguing. As the RPE barrier is tighter than the endothelial barrier, the significance of the RPE-derived
VEGF/outer BRB breakdown in DR has not been focused sufficiently. While the RPE-derived VEGF has been suggested to play a role in RPE-choriocapillaris interaction (9), RPE-derived soluble VEGF may regulate outer BRB function (37). The breakdown of the RPE barrier has been observed in diabetic patients (48). Some DR patients with no significant changes in the endothelial barrier demonstrated a severe outer BRB breakdown eventually (49). However, the significance of the RPE-derived VEGF and/or RPE barrier dysfunction in overall pathological changes in DR remains largely uninvestigated due to difficulties to distinguish the leakage from each BRB. With the development of cell-specific gene expression systems, a better understanding of the outer BRB dysfunction in DR is likely to emerge shortly.

In summary, the results from the current investigation and a previous study demonstrating a significant role for Müller cell-derived VEGF in retinal neovascularization (21) suggest that the Müller cell-derived VEGF plays a causative role in major pathological changes in DR, including retinal neovascularization, vascular leakage, vascular lesions, and inflammation. Therefore, Müller cells are a primary cellular source for signals that mediate pathological changes in DR. As VEGF is a target for clinical trials to treat DR, this information is valuable to the design of the delivery mechanisms for anti-VEGF therapies.

**Author contributions:** J.W. designed experiments, researched data, wrote/edited manuscript. X.X. contributed to discussion, reviewed/edited manuscript. M.H.E. researched data, wrote/edited manuscript. M.Z. researched data. Y-Z.L. designed experiments, researched data, wrote/edited manuscript.

**ACKNOWLEDGEMENTS**

We thank Dr. Y. Bai for technical assistance, Drs. J. Ma and B. Zhang for helpful suggestions, J. Wilkerson and Image Core Facility at Oklahoma Medical Research Foundation for transmission electron microscopy, and Core Facilities for services supported by NIH grants P20RR17703, P20RR024215, P30EY12190 and a grant from Research to Prevent Blindness, Inc. Characterization of the animal model in this study is a necessary experiment described in NIH R01EY20900 grant application. This study was supported by ADA grants 1-06-RA-76 and 1-10-BS-94, AHAF grant M2008-059, FFB grant BR-CMM-0808-0453-UOK, NIH R01 grant EY019494, OCAST grants HR09-058 and HR09-028, and Unrestricted Research Award from Hope for Vision.

**REFERENCES**


Müller cell-derived VEGF in diabetic retinopathy


Müller cell-derived VEGF in diabetic retinopathy


---

**Table 1** Body weights and blood glucose levels of normal or diabetic mice

<table>
<thead>
<tr>
<th>Group</th>
<th>Body weight (g)</th>
<th>Blood glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2 months</td>
<td>6 months</td>
</tr>
<tr>
<td>diabetic WT</td>
<td>21.46±1.60*</td>
<td>23.03±2.35*</td>
</tr>
<tr>
<td>diabetic KO</td>
<td>20.86±1.22*</td>
<td>23.29±0.63*</td>
</tr>
<tr>
<td>non-diabetic WT</td>
<td>28.17±2.28</td>
<td>32.43±1.66</td>
</tr>
<tr>
<td>non-diabetic KO</td>
<td>28.04±2.08</td>
<td>31.86±2.53</td>
</tr>
</tbody>
</table>

Data are means ± SEM, n=20-30. *p < 0.001 compared with non-diabetic WT or KO
Figure 1. Analysis of VEGF and HIF-1α expression in normal and diabetic conditional VEGF KO mice. A-B: Immunoblotting analysis for VEGF (A) and HIF-1α (B) in retinas from conditional VEGF KO mice and WT controls two months after diabetes. C-D: Confocal microscopic analysis of immunostained retinas for VEGF expression (green) in conditional VEGF KO mice and WT controls subjected to a diabetic stress. Blue: nuclear staining (DAPI). Scale bar equals to 40 μm. ONL: outer nuclear layer. INL: inner nuclear layer. Error bar: SEM. ***: p<0.001. ns: not significant. VEGF expression was significantly reduced in the retinas of conditional VEGF KO mice under normal or diabetic conditions. While diabetes up-regulated HIF-1α, no significant change in the levels of retinal HIF-1α was observed in diabetic conditional VEGF KO mice.
Figure 2. Analysis of retinal inflammation in conditional VEGF KO mice two months after inducing diabetes. A, B: FITC-conjugated ConA staining for adherent leukocytes (arrows) in retinal micro-vasculatures of diabetic conditional VEGF KO mice and WT controls. Scale bar represents 100 μm. C: Quantification of adherent leukocytes in retinal vasculatures of diabetic conditional VEGF KO mice and WT controls. D-E: immunoblotting analysis of ICAM-1 (D) and TNF-α (E) expression in conditional VEGF KO mice. F: immunoblotting analysis of NF-κB p65 phosphorylation in diabetic retinas of conditional VEGF KO mice. Error bar: SEM. ns: not significant. ***: p<0.001. Loss of Müller cell-derived VEGF caused a significant reduction in the number of adherent leukocytes, expression of ICAM-1 and TNF-α, and phosphorylated NF-κB p65 in diabetic retinas.
Figure 3. Analysis of retinal vascular leakage in conditional VEGF KO mice six months after onset of diabetes. A: immunoblotting analysis of retinal extravascular albumin in conditional VEGF KO mice. B-E: Microscopic images of retinal flat-mounts (B-C) and enlarged areas (D-E) showing fluorescently labeled albumin (arrows) in diabetic retinas of WT and conditional VEGF KO mice after injection with FITC-labeled albumin. Scale bars represent 100 μm. F: computer-assisted quantitative analysis of FITC-labeled albumin in diabetic retinas of conditional VEGF KO mice. Error bar: SEM. ***: p<0.001. Loss of Müller cell-derived VEGF caused a significant reduction in diabetes-induced retinal vascular leakage.
Figure 4. Analysis of tight-junction protein expression in retinas of conditional VEGF KO mice six months after diabetes. A-B: Immunoblotting and quantification of tight-junction protein occludin and ZO-1 in retinas of diabetic conditional VEGF KO mice. Error bar: SEM. ns: not significant. ***: p<0.001. C-F: Confocal microscopic analysis of immunostained tight-junction protein ZO-1 in retinal vasculature (C-D) from the diabetic retinas of conditional VEGF KO mice. Scale bars represent 50 μm. Loss of Müller cell-derived VEGF caused a significant attenuation of diabetes-induced depletion of tight-junction proteins occludin and ZO-1.
**Figure 5.** Retinal vascular histopathology in the conditional VEGF KO mice six months after inducing diabetes. A-C: Analysis of acellular capillaries (arrow heads) with trypsin digestion in diabetic retinas of the conditional VEGF KO mice and WT controls. Error bar: SEM. ***: p<0.001. Scale bar in B represents 50 μm. Scale bars in D-F represent 1 μm. D-F: representative TEM images for basement membrane thickness in retinal vascular capillaries. While the number of acellular capillaries was significant decreased in diabetic conditional VEGF KO mice, no apparent change in the thickness (arrow heads) of basement membrane was observed among all mice examined.
Figure 6. Retinal morphology and morphometry in conditional VEGF KO mice six month after onset of diabetes. A-B: morphology of H & E stained retinal sections. C: Thickness of outer nuclear layer (ONL), inner nuclear layer (INL), and total retina. D-E: Representative TEM images showing no detectable defects in diabetic retina of conditional VEGF KO mice. F: Average number of ganglion cells (GC). Scale bar equals to 50 μm in B and 1 μm in D-E, ns: not significant. Ch: choroid. CC: choriocapillaris. P: photoreceptors. No detectable changes in retinal thickness, numbers of ganglion cells, and retinal ultrastructure were observed in diabetic conditional VEGF KO mice.